Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Phenylbutazone sodium
RN: 129-18-0
UNII: 189M850I32
InChIKey: VYOUHDLOIRJOSW-UHFFFAOYSA-N

Note

  • A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.

Molecular Formulas

  • C19-H19-N2-O2.Na
  • C19-H20-N2-O2.Na

Molecular Weight

  • 330.3611
 

Classification Codes

  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Regulatory Agencies (Superlist Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Phenylbutazone sodium

Synonyms

  • 3,5-Dioxo-1,2-diphenyl-4-n-butylpyrazolidin sodium
  • 4-Butyl-1,2-diphenyl-3,5-pyrazolidinedione sodium salt
  • Butazolidine sodium
  • Diphenyldioxobutylpyrazolidine-butazolidine-sodium
  • EINECS 204-935-7
  • GP26872
  • Phenylbutazone sodium
  • Phenylbutazone sodium salt
  • Sodium butazolidine
  • Sodium phenylbutazone
  • Sodium salt of phenylbutazone
  • UNII-189M850I32

Systematic Names

  • 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl-, monosodium salt
  • 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione, sodium salt

Registry Numbers

CAS Registry Number

  • 129-18-0

FDA UNII

  • 189M850I32

System Generated Number

  • 0000129180

Molecular Formulas

Molecular Formulas

  • C19-H19-N2-O2.Na
  • C19-H20-N2-O2.Na

Molecular Formula Fragments

  • C19-H19-N2-O2
  • C19-H20-N2-O2
  • COMPONENT
  • Na

Structure Descriptors

InChI

1S/C19H19N2O2.Na/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;/h4-13H,2-3,14H2,1H3;/q-1;+1

InChIKey

VYOUHDLOIRJOSW-UHFFFAOYSA-N

Smiles

CCCC[c-]1c(=O)n(n(c1=O)c2ccccc2)c3ccccc3.[Na+]

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 169mg/kg (169mg/kg)   Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970.
mouse LD50 intravenous 94mg/kg (94mg/kg)   Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958.
mouse LD50 oral 476mg/kg (476mg/kg)   Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970.
mouse LD50 subcutaneous 257mg/kg (257mg/kg)   Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 63, Pg. 43, 1967.
rabbit LD50 intravenous 146mg/kg (146mg/kg)   Schweizerische Medizinische Wochenschrift. Vol. 84, Pg. 1315, 1954.
rat LD50 intravenous 113mg/kg (113mg/kg)   Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958.
rat LD50 oral 855mg/kg (855mg/kg)   Indian Journal of Physiology and Pharmacology. Vol. 5, Pg. 113, 1961.
rat LD50 subcutaneous 310mg/kg (310mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 229, 1958.
women LDLo oral 16mg/kg/D (16mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"

BLOOD: AGRANULOCYTOSIS

LUNGS, THORAX, OR RESPIRATION: STRUCTURAL OR FUNCTIONAL CHANGE IN TRACHEA OR BRONCHI
Annals of Internal Medicine. Vol. 39, Pg. 1096, 1953.